Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Genovis AB (publ.)
  6. Summary
    GENO   SE0002485979

GENOVIS AB (PUBL.)

(GENO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
66.6(c) 66.1(c) 63.9(c) 64.5(c) 66.2 Last
203 122 191 507 164 407 129 599 48 779 Volume
-8.64% -0.75% -3.33% +0.94% +2.64% Change
More quotes
Estimated financial data (e)
Sales 2021 74,7 M 8,22 M 8,22 M
Net income 2021 42,2 M 4,64 M 4,64 M
Net cash position 2021 68,8 M 7,57 M 7,57 M
P/E ratio 2021 99,2x
Yield 2021 -
Sales 2022 143 M 15,8 M 15,8 M
Net income 2022 55,2 M 6,08 M 6,08 M
Net cash position 2022 114 M 12,5 M 12,5 M
P/E ratio 2022 76,8x
Yield 2022 -
Capitalization 4 223 M 463 M 465 M
EV / Sales 2021 55,6x
EV / Sales 2022 28,7x
Nbr of Employees 33
Free-Float 95,4%
More Financials
Company
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically... 
More about the company
Ratings of Genovis AB (publ.)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about GENOVIS AB (PUBL.)
11/12INTERIM REPORT FOR July - September 2021
AQ
11/12Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
11/02Genovis - A Deal That Validates the Huge Potential
AQ
10/21GENOVIS : announces exclusive license agreement with Selecta Bioscience to develop and pro..
AQ
10/06GENOVIS' : New CFO To Assume Role January 2022
MT
10/06GENOVIS ( ) : hires new CFO
AQ
10/06Genovis AB (Publ.) Hires Magnus Långberg as the New CFO
CI
08/12GENOVIS : Half-year report for the first half of 2021
AQ
08/12Genovis AB (publ.) Announces Earnings Results for the Second Quarter Ended June 30, 202..
CI
06/07GENOVIS : and GlycoT Therapeutics enter into cross-licensing agreements on novel antibody ..
AQ
06/07Genovis AB (publ.) and GlycoT Therapeutics Enter into Cross-Licensing Agreements on Nov..
CI
05/20GENOVIS : Communiqué from Genovis AB (publ) Annual General Meeting May 20, 2021
AQ
05/20Genovis AB (Publ.) Announces Executive Changes
CI
04/29Genovis AB Publ. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
04/28GENOVIS : Annual Report 2020 published
AQ
More news
News in other languages on GENOVIS AB (PUBL.)

- No features available -

More news
Chart GENOVIS AB (PUBL.)
Duration : Period :
Genovis AB (publ.) Technical Analysis Chart | GENO | SE0002485979 | MarketScreener
Technical analysis trends GENOVIS AB (PUBL.)
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 64,50 SEK
Average target price 90,00 SEK
Spread / Average Target 39,5%
EPS Revisions
Managers and Directors
Fredrik Olsson Chief Executive Officer
Torben Vedel Stahl Jörgensen Chairman
Rolf Lood Vice President-Research & Development
Kenth Ingemar Petersson Independent Director
Mikael Lönn Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENOVIS AB (PUBL.)102.86%463
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.67.06%22 927
10X GENOMICS, INC.-2.60%16 439
BIOMÉRIEUX2.51%15 736
DIASORIN S.P.A.3.70%10 850
NATERA, INC.-6.99%8 756